Accelerate performance studies for assays subject to IVDR, including early phase clinical trials that test European patient samples.
In clinical trials involving European patients or their samples, adherence to IVDR is mandatory. IVDR necessitates performance studies to provide analytical and clinical evidence, which can lead to increased time and costs in early-phase trials, even when companion diagnostics development is not planned.
Discovery’s Kassel, Germany facility, operating under GCLP/CAP-CLIA standards and aligned with ISO 15189, holds the status of a Health Institution. This unique classification enables our clients to:
Discovery provides complete continuity across our global testing sites by using the same standard operating procedures (SOPs), the same laboratory information management system (LIMS), and one project manager for every global clinical trial.
IVDR Article 5 and Health Institution Status applies for institutions established in the EU only.
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
